
The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
Lisa Henderson interviews Gerd Arold of PRA about patient enrollment in early phase trials in Eastern Europe







